首页> Japanese journal of clinical oncology> A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).

A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).

导出 OA

翻译打印收藏纠错

第一作者： Nobuaki,Matsubara

第一单位： Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba nmatsuba@east.ncc.go.jp.

作者： Nobuaki,Matsubara ^[1] ; Hirotsugu,Uemura ^[2] ; Takefumi,Satoh ^[3] ; Hiroyoshi,Suzuki ^[4] ; Tsutomu,Nishiyama ^[5] ; Hiroji,Uemura ^[6] ; Katsuyoshi,Hashine ^[7] ; Keiichiro,Imanaka ^[8] ; Seiichiro,Ozono ^[9] ; Hideyuki,Akaza ^[10]

作者单位： Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba nmatsuba@east.ncc.go.jp. ^[1] Department of Urology, Kinki University Faculty of Medicine, Osaka. ^[2] Department of Urology, Kitasato University School of Medicine, Kanagawa. ^[3] Department of Urology, Toho University Sakura Medical Center, Chiba. ^[4] Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University, Graduate School of Medical and Dental Sciences, Niigata. ^[5] Department of Urology, Yokohama City University Graduate School of Medicine, Kanagawa. ^[6] Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama. ^[7] Janssen Pharmaceutical K.K, Tokyo. ^[8] Department of Urology, Hamamatsu University School of Medicine, Shizuoka. ^[9] Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ^[10]

关键词 abiraterone acetate chemotherapy-na?ve metastatic castration-resistant prostate cancer prednisolone prostate specific antigen